Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]
Naseem A +3 more
europepmc +1 more source
TP53-aberrated CLL: is BTK inhibitor monotherapy enough? [PDF]
Niemann CU.
europepmc +1 more source
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting. [PDF]
Shah BD, Xue M, Furnback W, Yang K.
europepmc +1 more source
Integrating single-cell biophysical and transcriptomic features to resolve functional heterogeneity in mantle cell lymphoma. [PDF]
Zhang Y +20 more
europepmc +1 more source
Acalabrutinib May Offer a New Therapeutic Approach for Consolidation and Maintenance of Primary CNS Lymphoma with Expression of MYD88 and CD79B Gene Variants: A Case Report and Literature Review of Primary CNS Lymphoma in the BTKi Era. [PDF]
Allison E +3 more
europepmc +1 more source
Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. [PDF]
Chohan KL +13 more
europepmc +1 more source
Addressing cardiovascular toxicities of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukaemia: practical recommendations for haematologists in central and eastern Europe. [PDF]
Aurer I +13 more
europepmc +1 more source
A Case of Metastatic Spinal Cord Compression in a Patient With Coexisting Chronic Lymphocytic Leukemia and Colon Cancer. [PDF]
Abbas K, Nagumantry S.
europepmc +1 more source
Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]
Visentin A, Mauro FR.
europepmc +1 more source

